Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
dextromethorphan hydrobromide and chlorpheniramine maleate s
2025-01-21

Acetaldehyde One of the most common environmental aldehydes is acetaldehyde (CH2CHO). Acetaldehyde, which is highly volatile, has been classified as a Group I human carcinogen by the International Agency for Research on Cancer [30]. Aldehydes can form DNA adducts, including ring-open forms of cro
-
Adiponectin also suppresses inflammatory stimuli induced NF
2025-01-21

Adiponectin also suppresses inflammatory stimuli-induced NF-kappaB activation, which may significantly contribute to the anti-diabetic and anti-atherogenic effects of adiponectin (Ouchi et al., 2000). The downstream mediators of AdipoR1 and AdipoR2, RPPAR and AMPK increase inflammatory responses by
-
The physiological effect of adenosine is now considered
2025-01-21

The physiological effect of adenosine is now considered a new direction in halting the progression of organ damage in cardiovascular disease [24], [25], [26]. Adenosine has diverse functions, depending on its interaction with different receptor subtypes: A1, A2A, A2B, and A3[24], [25], [26]. Stimula
-
In summary we suggest that both cofilin and gelsolin
2025-01-21

In summary, we suggest that both cofilin and gelsolin are essential factors that regulate sperm capacitation and the acrosomal exocytosis by modulating actin. The relationships between activation/inactivation of cofilin and gelsolin suggest that inhibition of cofilin is important for allowing F-acti
-
Comparatively cell based assays appear to be the most
2025-01-21

Comparatively, cell-based assays appear to be the most sensitive method to detect patient autoantibodies directed at neurotransmitter receptors. Leite et al. demonstrated that many α-BTX RIA seronegative myasthenic patients do have autoantibodies against the AChR when a highly sensitive immunofluore
-
br LO and the secretase complex Supporting this concept duri
2025-01-21

5LO and the γ-secretase complex Supporting this concept, during a recent trial testing the γ-secretase inhibitor semagacestat (LY 450139), AD patients actually experienced a functional decline compared to patients who took a placebo in addition to several other significant adverse effects (Doody
-
The cellular mechanism underlying the CGS mediated inhibitio
2025-01-21

The cellular mechanism underlying the CGS12066-mediated inhibition of glutamate release from hippocampal nerve terminals through presynaptic 5-HT1B receptors remains to be elucidated. 5-HT1B receptors are coupled to PTX-sensitive G proteins (Gi or Go) that have been shown to inhibit AC activity as w
-
An AXL decoy receptor with enhanced GAS binding
2025-01-21

An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer pemetrexed disodium and a murine breast cancer cell line in grafting assa
-
Whole body loss of ACLY is early embryonic
2025-01-21

Whole-body loss of ACLY is early embryonic lethal, indicating that it serves non-redundant roles during development (Beigneux et al., 2004). Silencing or inhibition of ACLY suppresses the proliferation of many cancer cell lines and impairs tumor growth (Bauer et al., 2005, Hanai et al., 2012, Hatziv
-
Compound was synthesized by reacting amino methoxybenzoate w
2025-01-20

Compound 31 was synthesized by reacting 5-amino-2-methoxybenzoate (28) with ethanesulfonyl chloride in the presence of pyridine in DCM to give sulfonamide 29. Hydrolysis of 29 by aqueous sodium hydroxide afforded the resveratrol 30 which was converted to the acid chloride by heating in thionyl chlo
-
SMI-4a receptor It is well known that neurosteroids
2025-01-20

It is well-known that neurosteroids such as testosterone and their metabolites endogenously modulate neural excitability in animals and humans. Testosterone has protective effects against seizures induced by KA and PTZ (Frye et al., 2001b; Reddy, 2004b). Estrogens, on the other hand, have proconvuls
-
Despite these conflicting data about COX ER correlations a l
2025-01-20

Despite these conflicting data about COX-2/ER correlations, a large body of evidence supports that elevated COX-2 expression in breast cancer is a constant feature of high stage disease and a predictor of worse outcome. Upregulation of COX-2 protein has been identified in approximately 40% of cases
-
br The role of apelin in cancer Studies
2025-01-20

The role of apelin in cancer Studies on cancers are intensively conducted worldwide. It is thought that this large family of diseases is among the most studied. The researchers test newly-discovered substances hoping to find remedies and diagnostic indices for this illness. One of such substances
-
To the best of our knowledge
2025-01-20

To the best of our knowledge, this is the first study documenting the SCC modulatory effect at central and kidney level on the shift in the vasoconstrictor-vasodilator ratio of mRNA expression of angiotensin receptors toward vasoconstriction in XY-SCC and/or vasodilation in XX-SCC mice. From these r
-
The increased occurrence of ARIA E in APOE carriers in
2025-01-20

The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied
15825 records 31/1055 page Previous Next First page 上5页 3132333435 下5页 Last page